Gradient Capital Advisors LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 4.5% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 8,272 shares of the company’s stock after selling 394 shares during the period. Gradient Capital Advisors LLC’s holdings in Johnson & Johnson were worth $1,282,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Moneta Group Investment Advisors LLC grew its position in shares of Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $4,609,399,000. Morgan Stanley grew its position in shares of Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Nordwand Advisors LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $785,273,000. Finally, Price T Rowe Associates Inc. MD grew its position in Johnson & Johnson by 15.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after buying an additional 3,849,148 shares in the last quarter. Institutional investors own 67.57% of the company’s stock.
Johnson & Johnson Stock Down 1.4 %
Shares of JNJ opened at $163.26 on Tuesday. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04. The stock has a market capitalization of $424.27 billion, a price-to-earnings ratio of 34.15, a PEG ratio of 2.83 and a beta of 0.55. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a fifty day moving average of $160.78 and a 200-day moving average of $162.82.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd were given a dividend of $1.19 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 2.92%. The ex-dividend date of this dividend was Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 99.58%.
Insider Buying and Selling
In related news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on JNJ shares. UBS Group started coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. Credit Suisse Group increased their price target on Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Raymond James reduced their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 19th. TheStreet downgraded Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Finally, Citigroup began coverage on Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 target price for the company. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $171.57.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Tesla Production Cranks Into High Gear, Shares Follow
- Ford Soars 30% YTD After Breaking Out: What’s Next?
- Acuity Brands Lights Up Opportunity In The Industrial Sector
- Overstock Looks Beyond Overbought After Bed Bath Re-Brand
- Tecnoglass Shines Bright As Analysts Bullish On Growth Potential
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
